{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:26:37Z","timestamp":1773300397822,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006635","name":"Robin Hood Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004856","name":"New York State Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The social determinants of health that influence steps in the entire Hepatitis C Virus (HCV) treatment cascade must be identified to achieve HCV elimination goals. This project aimed to evaluate the association of these factors with HCV treatment completion and return for sustained virologic response (SVR) testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used retrospective cohort data from our primary care-based HCV treatment program that provides comprehensive harm reduction care to those who use or formerly used drugs. Among persons who began direct-acting antiviral HCV treatment between December 2014 and March 2018, we identified two outcomes: HCV treatment completion and return for SVR assessment 12\u00a0weeks after treatment end. Several predictors were ascertained including sociodemographic information, substance use, psychiatric symptoms and history, housing instability, and HCV treatment regimen. We then evaluated associations between predictors and outcomes using univariate and multivariable statistical methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From a cohort of 329 patients treated in an urban primary care center, multivariable analysis identified housing instability as a single significant predictor for HCV treatment completion (odds ratio [OR]: 0.3; 95% confidence interval [CI]: 0.1\u20130.9). Among patients completing treatment, 226 (75%) returned for SVR assessment; the sole predictor of this outcome was Medicaid as primary insurance (compared to other insurances; OR 0.3; 0.1\u20130.7).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Innovative strategies to help unstably housed persons complete HCV treatment are urgently needed in order to reach HCV elimination targets. Educational and motivational strategies should be developed to promote individuals with Medicaid in particular to return for SVR viral load testing, a critical post-treatment component of the HCV treatment cascade.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>Not applicable.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12954-021-00486-4","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:03:18Z","timestamp":1617184998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6466-9016","authenticated-orcid":false,"given":"Jacob","family":"Ziff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Dvir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Riazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma","family":"Toribio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Oster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Sigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"486_CR1","unstructured":"WHO. Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: The World Health Organization; 2016."},{"issue":"25","key":"486_CR2","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405\u201316.","journal-title":"N Engl J Med"},{"issue":"20","key":"486_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"486_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631\u201340.","journal-title":"JAMA"},{"issue":"3","key":"486_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/liv.14324","volume":"40","author":"H Razavi","year":"2020","unstructured":"Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40(3):522\u20139.","journal-title":"Liver Int"},{"issue":"10","key":"486_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/aje\/kwn237","volume":"168","author":"H Hagan","year":"2008","unstructured":"Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099\u2013109.","journal-title":"Am J Epidemiol"},{"issue":"9791","key":"486_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (London, England). 2011;378(9791):571\u201383.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"486_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","volume":"171","author":"IT Williams","year":"2011","unstructured":"Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982\u20132006. Arch Intern Med. 2011;171(3):242\u20138.","journal-title":"Arch Intern Med"},{"key":"486_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.addbeh.2019.04.023","volume":"96","author":"R Irvin","year":"2019","unstructured":"Irvin R, Chander G, Falade-Nwulia O, Astemborski J, Starbird L, Kirk GD, et al. Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. Addict Behav. 2019;96:56\u201361.","journal-title":"Addict Behav"},{"issue":"5","key":"486_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/ADM.0000000000000147","volume":"9","author":"C Woodrell","year":"2015","unstructured":"Woodrell C, Weiss J, Branch A, Gardenier D, Krauskopf K, Kil N, et al. Primary care-based hepatitis C treatment outcomes with first-generation direct-acting agents. J Addict Med. 2015;9(5):405\u201310.","journal-title":"J Addict Med"},{"issue":"1","key":"486_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","volume":"3","author":"E Hughes","year":"2016","unstructured":"Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"486_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2105\/AJPH.2016.303059","volume":"106","author":"E Trager","year":"2016","unstructured":"Trager E, Khalili M, Masson CL, Vittinghoff E, Creasman J, Mangurian C. Hepatitis C screening rate among underserved adults with serious mental illness receiving care in California community mental health centers. Am J Public Health. 2016;106(4):740\u20132.","journal-title":"Am J Public Health"},{"issue":"5","key":"486_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s11524-017-0174-x","volume":"94","author":"MM Ford","year":"2017","unstructured":"Ford MM, Desai PS, Maduro G, Laraque F. Neighborhood inequalities in hepatitis C mortality: spatial and temporal patterns and associated factors. J Urban Health. 2017;94(5):746\u201355.","journal-title":"J Urban Health"},{"issue":"2","key":"486_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/eurpub\/cky142","volume":"29","author":"N Nikoo","year":"2019","unstructured":"Nikoo N, Javidanbardan S, Akm M, Hakobyan S, Nikoo M, Kwan C, et al. Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: at home\/Chez Soi Study, Vancouver, BC. Eur J Public Health. 2019;29(2):242\u20137.","journal-title":"Eur J Public Health"},{"issue":"4","key":"486_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11524-018-0277-z","volume":"95","author":"AG Wurcel","year":"2018","unstructured":"Wurcel AG, Burke DJ, Wang JJ, Engle B, Noonan K, Knox TA, et al. The burden of untreated HCV infection in hospitalized inmates: a hospital utilization and cost analysis. J Urban Health. 2018;95(4):467\u201373.","journal-title":"J Urban Health"},{"key":"486_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","volume":"72","author":"ME Beiser","year":"2019","unstructured":"Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019;72:129\u201337.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"486_CR17","doi-asserted-by":"publisher","first-page":"ofy173","DOI":"10.1093\/ofid\/ofy173","volume":"5","author":"ER Cachay","year":"2018","unstructured":"Cachay ER, Hill L, Torriani F, Ballard C, Grelotti D, Aquino A, et al. Predictors of missed hepatitis c intake appointments and failure to establish hepatitis C care among patients living with HIV. Open Forum Infect Dis. 2018;5(7):ofy173.","journal-title":"Open Forum Infect Dis."},{"issue":"8","key":"486_CR18","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319\u201327.","journal-title":"Lancet HIV"},{"key":"486_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","volume":"62","author":"EB Cunningham","year":"2018","unstructured":"Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy. 2018;62:14\u201323.","journal-title":"Int J Drug Policy"},{"key":"486_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugpo.2018.10.004","volume":"62","author":"J Grebely","year":"2018","unstructured":"Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, et al. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018;62:94\u2013103.","journal-title":"Int J Drug Policy"},{"key":"486_CR21","unstructured":"Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, et al. Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. Clin Infect Dis. 2019."},{"key":"486_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","volume":"47","author":"P Read","year":"2017","unstructured":"Read P, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209\u201315.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"486_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/ADM.0000000000000415","volume":"12","author":"JB Trabut","year":"2018","unstructured":"Trabut JB, Barrault C, Charlot H, Carmona D, Bourdel A, Benslimane M, et al. Integrated care for the use of direct-acting antivirals in patients with chronic hepatitis c and substance use disorder. J Addict Med. 2018;12(5):346\u201352.","journal-title":"J Addict Med"},{"issue":"3","key":"486_CR24","doi-asserted-by":"publisher","first-page":"ofz070","DOI":"10.1093\/ofid\/ofz070","volume":"6","author":"ER Cachay","year":"2019","unstructured":"Cachay ER, Mena A, Morano L, Benitez L, Maida I, Ballard C, et al. Predictors of hepatitis C treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus. Open Forum Infect Dis. 2019;6(3):ofz070.","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"486_CR25","doi-asserted-by":"publisher","first-page":"055","DOI":"10.1093\/ofid\/ofz055","volume":"6","author":"C Rossi","year":"2019","unstructured":"Rossi C, Young J, Martel-Laferriere V, Walmsley S, Cooper C, Wong A, et al. Direct-acting antiviral treatment failure among hepatitis C and HIV-coinfected patients in clinical care. Open Forum Infect Dis. 2019;6(3):055.","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"486_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/jvh.13218","volume":"27","author":"KE Daniel","year":"2020","unstructured":"Daniel KE, Saeian K, Rizvi S. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat. 2020;27(2):195\u2013204.","journal-title":"J Viral Hepat"},{"key":"486_CR27","unstructured":"Ward JW. The Nobel Prize for discovery of HCV is a call to end hepatitis. The Lancet."},{"key":"486_CR28","unstructured":"Joel Ackelsberg FL, Borneschlegel K, Rude E, Varma JK. Hepatitis C in New York City: state of the epidemic and action plan. In: Hygiene NYCDoHaM, editor. 2019."},{"issue":"4","key":"486_CR29","first-page":"329","volume":"24","author":"TM Vu","year":"2018","unstructured":"Vu TM, Toribio W, Riazi F, Ciprian G, Gibbs N, Giardina M, et al. Increasing access to hepatitis C virus medications: a program model using patient navigators and specialty pharmacy to obtain prior authorization approval. J Manag Care Spec Pharm. 2018;24(4):329\u201333.","journal-title":"J Manag Care Spec Pharm"},{"issue":"41","key":"486_CR30","doi-asserted-by":"publisher","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","volume":"21","author":"Y Lurie","year":"2015","unstructured":"Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567\u201383.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"486_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvh.13110","volume":"26","author":"D Back","year":"2019","unstructured":"Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat. 2019;26(8):951\u201360.","journal-title":"J Viral Hepat"},{"issue":"11","key":"486_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/jvh.13175","volume":"26","author":"P Read","year":"2019","unstructured":"Read P, Gilliver R, Kearley J, Lothian R, Cunningham EB, Chronister KJ, et al. Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection. J Viral Hepat. 2019;26(11):1301\u201310.","journal-title":"J Viral Hepat"},{"key":"486_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1471-2458-9-270","volume":"9","author":"C Kim","year":"2009","unstructured":"Kim C, Kerr T, Li K, Zhang R, Tyndall MW, Montaner JS, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health. 2009;9:270.","journal-title":"BMC Public Health"},{"key":"486_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.","journal-title":"Harm Reduct J"},{"key":"486_CR35","doi-asserted-by":"publisher","first-page":"107744","DOI":"10.1016\/j.drugalcdep.2019.107744","volume":"206","author":"E Fortier","year":"2020","unstructured":"Fortier E, Sylvestre MP, Artenie AA, Minoyan N, Jutras-Aswad D, Roy E, et al. Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montreal Canada. Drug Alcohol Depend. 2020;206:107744.","journal-title":"Drug Alcohol Depend"},{"key":"486_CR36","unstructured":"Raphael D, Raphael D. (eds). Social determinants of health: Canadian perspectives, 2nd edn. Toronto: Canadian Scholars\u2019 Press; 2009."},{"key":"486_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12927\/hcq.2016.24479","volume":"18","author":"C Forchuk","year":"2016","unstructured":"Forchuk C. Social determinants of health: housing and income. Healtcare Q. 2016;18:27\u201331.","journal-title":"Healtcare Q"},{"key":"486_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-publhealth-031210-101218","volume":"32","author":"P Braveman","year":"2011","unstructured":"Braveman P, Egerter S, Williams DR. The social determinants of health: coming of age. Annu Rev Public Health. 2011;32:381\u201398.","journal-title":"Annu Rev Public Health"},{"key":"486_CR39","volume-title":"Homelessness, housing, and mental health: finding truths, creating change","author":"C Forchuk","year":"2011","unstructured":"Forchuk C. Homelessness, housing, and mental health: finding truths, creating change. Toronto: Canadian Scholars\u2019 Press Inc; 2011."},{"issue":"4","key":"486_CR40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.14266","volume":"40","author":"A Brown","year":"2020","unstructured":"Brown A, Welzel TM, Conway B, Negro F, Brau N, Grebely J, et al. Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials. Liver Int. 2020;40(4):778\u201386.","journal-title":"Liver Int"},{"issue":"2\u20133","key":"486_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","volume":"88","author":"J Ahern","year":"2007","unstructured":"Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88(2\u20133):188\u201396.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"486_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11524-012-9753-z","volume":"90","author":"C Latkin","year":"2013","unstructured":"Latkin C, Davey-Rothwell M, Yang JY, Crawford N. The relationship between drug user stigma and depression among inner-city drug users in Baltimore, MD. J Urban Health. 2013;90(1):147\u201356.","journal-title":"J Urban Health"},{"issue":"1","key":"486_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"key":"486_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-7517-3-31","volume":"3","author":"CL Cooper","year":"2006","unstructured":"Cooper CL, Mills EJ. Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduct J. 2006;3:31.","journal-title":"Harm Reduct J"},{"key":"486_CR45","doi-asserted-by":"crossref","unstructured":"Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, et al. Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs. Clin Infect Dis. 2020.","DOI":"10.1093\/cid\/ciaa253"},{"issue":"10","key":"486_CR46","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep4.1246","volume":"2","author":"NJ Kim","year":"2018","unstructured":"Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver disease monitoring practices after hepatitis C cure in the underserved population. Hepatol Commun. 2018;2(10):1274\u201383.","journal-title":"Hepatol Commun"},{"issue":"12","key":"486_CR47","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1007\/s10620-018-5247-5","volume":"63","author":"MC Marshall","year":"2018","unstructured":"Marshall MC, Herrera JL. Lack of patient compliance in real-world practice negatively affects sustained viral response rates to direct acting agent therapy for hepatitis C. Dig Dis Sci. 2018;63(12):3228\u201332.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"486_CR48","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1007\/s10620-018-5205-2","volume":"63","author":"RA Stewart","year":"2018","unstructured":"Stewart RA, MacDonald BR, Chu TC, Moore JD, Fasanmi EO, Ojha RP. Ledipasvir\/sofosbuvir effectively treats hepatitis c virus infections in an underserved population. Dig Dis Sci. 2018;63(12):3233\u201340.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"486_CR49","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1007\/s10620-018-5231-0","volume":"63","author":"AN Tran","year":"2018","unstructured":"Tran AN, Sachdev R, Fricker ZP, Leber M, Zahorian T, Shah B, et al. Intensive pharmacy care improves outcomes of hepatitis C treatment in a vulnerable patient population at a safety-net hospital. Dig Dis Sci. 2018;63(12):3241\u20139.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"486_CR50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","volume":"70","author":"C Coyle","year":"2019","unstructured":"Coyle C, Moorman AC, Bartholomew T, Klein G, Kwakwa H, Mehta SH, et al. The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA. Hepatology. 2019;70(2):476\u201386.","journal-title":"Hepatology"},{"issue":"8","key":"486_CR51","doi-asserted-by":"publisher","first-page":"e0161241","DOI":"10.1371\/journal.pone.0161241","volume":"11","author":"K Bourgi","year":"2016","unstructured":"Bourgi K, Brar I, Baker-Genaw K. Health disparities in hepatitis C screening and linkage to care at an integrated health system in Southeast Michigan. PLoS ONE. 2016;11(8):e0161241.","journal-title":"PLoS ONE"},{"issue":"1","key":"486_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/apt.15291","volume":"50","author":"J Chhatwal","year":"2019","unstructured":"Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019;50(1):66\u201374.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"486_CR53","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1090198118822724","volume":"46","author":"T Thompson","year":"2019","unstructured":"Thompson T, McQueen A, Croston M, Luke A, Caito N, Quinn K, et al. Social needs and health-related outcomes among medicaid beneficiaries. Health Educ Behav. 2019;46(3):436\u201344.","journal-title":"Health Educ Behav"},{"issue":"2","key":"486_CR54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2105\/AJPH.2003.035576","volume":"95","author":"DG Blazer","year":"2005","unstructured":"Blazer DG, Sachs-Ericsson N, Hybels CF. Perception of unmet basic needs as a predictor of mortality among community-dwelling older adults. Am J Public Health. 2005;95(2):299\u2013304.","journal-title":"Am J Public Health"},{"issue":"6","key":"486_CR55","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1177\/0898264306293261","volume":"18","author":"N Sachs-Ericsson","year":"2006","unstructured":"Sachs-Ericsson N, Schatschneider C, Blazer DG. Perception of unmet basic needs as a predictor of physical functioning among community-dwelling older adults. J Aging Health. 2006;18(6):852\u201368.","journal-title":"J Aging Health"},{"key":"486_CR56","unstructured":"Machledt D. Addressing the social determinants of health through medicaid managed care. The Commonwealth Fund. 2017."},{"issue":"5","key":"486_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.japh.2018.06.013","volume":"58","author":"SL Keast","year":"2018","unstructured":"Keast SL, Holderread B, Cothran T, Skrepnek GH. Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost. J Am Pharm Assoc. 2018;58(5):485\u201391.","journal-title":"J Am Pharm Assoc."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-021-00486-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T13:36:56Z","timestamp":1698154616000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00486-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}